vididencel
mendus
['alison', 'ovarian', 'mendus']
updated clinical data from our alison trial evaluating #vididencel in #ovariancancer were presented at #aacr23. the interim analysis shows that vididencel is capable of inducing durable #tcell responses against tumor-associated antigens &amp; continues to be safe and well tolerated. 
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes, while preserving quality of life.